Teza Capital Management LLC Boosts Stake in Insulet Co. (NASDAQ:PODD)

Teza Capital Management LLC boosted its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 53.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,714 shares of the medical instruments supplier's stock after buying an additional 1,648 shares during the quarter. Teza Capital Management LLC's holdings in Insulet were worth $1,231,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Horizon Investments LLC raised its stake in Insulet by 3.1% in the 4th quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock valued at $362,000 after acquiring an additional 42 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Insulet by 1.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier's stock valued at $1,146,000 after purchasing an additional 43 shares during the period. Wilmington Savings Fund Society FSB lifted its stake in shares of Insulet by 9.6% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier's stock worth $140,000 after buying an additional 47 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Insulet by 2.3% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier's stock worth $552,000 after buying an additional 48 shares during the period. Finally, Steward Partners Investment Advisory LLC boosted its holdings in shares of Insulet by 5.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,050 shares of the medical instruments supplier's stock worth $274,000 after buying an additional 50 shares during the period.

Insulet Trading Down 1.1%

Shares of NASDAQ PODD traded down $3.50 during midday trading on Thursday, reaching $321.00. The stock had a trading volume of 991,446 shares, compared to its average volume of 708,855. Insulet Co. has a twelve month low of $170.67 and a twelve month high of $329.33. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The company's 50 day moving average price is $268.73 and its 200 day moving average price is $268.38. The firm has a market cap of $22.59 billion, a price-to-earnings ratio of 55.44, a price-to-earnings-growth ratio of 3.62 and a beta of 1.26.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. During the same period last year, the business posted $0.73 EPS. The business's revenue was up 28.8% compared to the same quarter last year. As a group, sell-side analysts expect that Insulet Co. will post 3.92 EPS for the current year.

Analysts Set New Price Targets

PODD has been the topic of a number of research reports. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Insulet in a report on Friday, May 16th. Wells Fargo & Company set a $322.00 price objective on Insulet in a research note on Monday, April 28th. Royal Bank of Canada initiated coverage on Insulet in a research note on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price target for the company. Oppenheimer boosted their price objective on shares of Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Finally, Raymond James reaffirmed an "outperform" rating and set a $328.00 price target (up from $294.00) on shares of Insulet in a report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $308.00.

Insider Buying and Selling

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the sale, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. This trade represents a 36.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP John W. Kapples sold 5,278 shares of the stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the transaction, the senior vice president now owns 23,180 shares in the company, valued at approximately $7,382,134.60. This represents a 18.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is owned by insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.